Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
OTLK
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-0.60
vs -1.80
Q2.23
N/A
-1.60
vs -1.60
Q3.23
N/A
-1.00
vs -0.06
Q4.23
N/A
-0.80
vs -1.60
Q1.24
N/A
-1.55
vs -0.60
Q2.24
N/A
-0.83
vs -1.60
Q3.24
N/A
-0.77
vs -1.00
Q4.24
N/A
-0.89
vs -0.80
Q1.25
N/A
-0.54
vs -1.55
Q2.25
N/A
-0.47
vs -0.83
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
NA vs NA
Q4.23
NA
NA vs NA
Q1.24
NA
NA vs NA
Q2.24
NA
NA vs NA
Q3.24
NA
NA vs NA
Q4.24
NA
NA vs NA
Q1.25
NA
628.3K vs NA
Q2.25
NA
1.6M vs NA
Return on Equity
QoQ
Q1.23
-63%
-0.63
vs -1.18
Q2.23
+376%
3.76
vs -0.63
Q3.23
+90%
0.9
vs 3.76
Q4.23
+46%
0.46
vs 0.9
Q1.24
+85%
0.85
vs 0.46
Q2.24
-53%
-0.53
vs 0.85
Q3.24
-8%
-0.08
vs -0.53
Q4.24
0%
-0.00
vs -0.08
Institutionnal Ownership
QoQ
Q1.23
79
79
vs 74
7%
Q2.23
85
85
vs 79
8%
Q3.23
78
78
vs 85
-8%
Q4.23
85
85
vs 78
9%
Q1.24
56
56
vs 85
-34%
Q2.24
65
65
vs 56
16%
Q3.24
70
70
vs 65
8%
Q4.24
61
61
vs 70
-13%
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
globenewswire.com
9 hours ago
globenewswire.com
9 hours ago
Forecast
NaN%2025-Revenue
-348%2025-EPS
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
BTIG
upgradePrevious: Not converted
2024-03-27
Now: Buy
Guggenheim
upgradePrevious: Not converted
2024-01-25
Now: Buy
Brookline Capital
upgradePrevious: Not converted
2024-01-25
Now: Buy
H.C. Wainwright
upgradePrevious: Not converted
2023-11-03
Now: Buy
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
NASDAQ
Unprofitable
Unprofitable
-0.02 ( -1.29%)
Relative Strenght
8
Volume Buzz
-56%
Earning Acce
Yes
Dist 52w H.
84%